News from the American Diabetes Association’s Scientific Sessions

Key stories from this year’s American Diabetes Association Scientific Sessions, presented by the Journal of Diabetes Nursing.

To celebrate #DiabetesWeek (13–19 June), the Journal of Diabetes Nursing is sharing the latest news from the American Diabetes Association meeting that took place in New Orleans last week.

Click here to read the report.

Share this article

News from the American Diabetes Association’s Scientific Sessions

Tirzepatide reduces body weight by up to 22.5% in participants with overweight or obesity

UK Kidney Association releases guideline on SGLT2 inhibitor use

EMPEROR-Preserved: Empagliflozin first therapeutic agent to demonstrate benefits in people with HFpEF

Dapagliflozin approved in the EU for treatment of CKD in people with and without type 2 diabetes

Diabetes before, during and after pregnancy

Early-onset and youth-onset type 2 diabetes: new factsheet

Tirzepatide reduces body weight by up to 22.5% in participants with overweight or obesity

Top-line results from the SURMOUNT-1 clinical trial.

5 May 2022

UK Kidney Association releases guideline on SGLT2 inhibitor use

The UK Kidney Association has released its Clinical Practice Guideline on SGLT2 inhibitor use in adults with kidney disease.

19 Oct 2021

EMPEROR-Preserved: Empagliflozin first therapeutic agent to demonstrate benefits in people with HFpEF

Composite of cardiovascular death or hospitalisation for heart failure significantly reduced by 21% with empagliflozin compared to placebo.

31 Aug 2021

For the latest news and articles

Resources

Journals

Useful information